Orange Blossom Family Health’s HIV Well Program offers comprehensive testing and treatment services for HIV prevention and support.

According to national health department data, Black and Hispanic populations with HIV are overrepresented compared to Whites in the general population. From 2011 to 2015, HIV incidence increased by 12.1%, with a decrease among Whites but an increase among Blacks and Hispanics. The majority of those with HIV were male(78.8%), and the highest infection rates were among those aged 20-24. In Florida, men who have sex with men(MSM) were the primary exposure category for males, while heterosexual contact was the primary category for females. The HIVWell program aims to address issues of access to healthcare to these populations by providing outreach, testing, prevention, care, and support services to the underserved MSM population in the Orlando Metropolitan Area. Funded by a grant from SAMHSA we seek to improve behavioral and medical health care for Black MSM, Hispanic MSM, and White MSM aged 29 and under, as well as MSM aged 30 and under.

Through the HIV Well program, participants learn their status, effective prevention tools and support and treatments for those who are HIV positive. It all begins with testing. Contact us to find the most convenient testing location near you.

Tim Collins
HIV Well Program Manager

Orange Blossom Family Health is proud to have been chosen to partner with the Centers for Disease Control (CDC) to bring a High-Impact HIV Prevention Program to our community. This program provides testing and referrals for PrEP and HIV care as part of the Ending the HIV Epidemic initiative from the Department of Health and Human Services. Diagnose, Treat, Prevent and Respond are the four pillars that will help us all to collectively reach this goal. The Orlando Metropolitan Area is second in the state of Florida and third in the entire country for new HIV infections. The CDC is investing in communities most affected by HIV as we all work together to end the HIV epidemic in the United States by 2030.

Micko Corbin
BAM Program Manager

Prevention Treatments

PrEP, or pre-exposure prophylaxis, is medicine for people with a negative HIV status who are at risk for HIV through sexual intercourse, intravenous drug use, or percutaneous exposure to blood.

Currently, there are two FDA – approved daily oral medications for PrEP (Truvada – Emtricitabine / Tenofovir) and (Descovy – Emtricitabine / Tenofovir). A long-acting, bi-monthly injectable form of PrEP (Apretude-cabotegravir) has also been approved by the FDA. After confidential consultation with our service providers, our in-house pharmacy can prescribe the appropriate medications.

Post Exposure Treatment

nPEP (post-exposure prophylaxis) means taking medicine to prevent HIV after a possible exposure. nPEP should be used only in emergency situations and must be started within 72 hours after a possible exposure to HIV.

Possible exposures include condom-less intercourse, or a percutaneous exposure to blood when the source has known HIV or is at high-risk of having HIV (eg, man who has sex with men [MSM], injection drug user, sex worker).

Patients qualifying for nPEP is given as a 28-day course, 3-drug regimen most commonly containing tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and either raltegravir (RAL) OR dolutegravir (DTG).

Isabel Hudson
HIV PrEP Navigator